Free Trial
NASDAQ:XBIO

Xenetic Biosciences Q1 2025 Earnings Report

Xenetic Biosciences logo
$3.20 -0.04 (-1.20%)
As of 08/1/2025 03:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xenetic Biosciences EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.72
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Xenetic Biosciences Revenue Results

Actual Revenue
$0.59 million
Expected Revenue
$0.52 million
Beat/Miss
Beat by +$74.00 thousand
YoY Revenue Growth
N/A

Xenetic Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
8:30AM ET

Upcoming Earnings

Xenetic Biosciences' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Monday, August 11, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Xenetic Biosciences Earnings Headlines

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
Xenetic Biosciences Inc
3XB0.SG,0P0001N0OC,0 (3XB0.SG)
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

View Xenetic Biosciences Profile

More Earnings Resources from MarketBeat